Phase 3 Prurigo Nodularis Trial Shows Benefit With Nemolizumab Phase 3 Prurigo Nodularis Trial Shows Benefit With Nemolizumab

From prior studies of nemolizumab, ' we know that it modulates pruritus, but also alters keratinocyte differentiation, inflammation, and fibrosis, ' according to Shawn G. Kwatra, MD.MDedge News

Source: Medscape Dermatology Headlines - March 22, 2023 Category: Dermatology Tags: Dermatology News Source Type: news